Real world utilization of 91 day extended levonorgestrel-containing combined oral contraceptives in Europe: a multinational database study
Creators: name: Kaplan, Sigal
name: Toussi, Massoud
name: Evans, Alison
name: Dhanda, Sandeep
name: Debabrata Roy
name: Lass, Amir
Publisher: name: Taylor & Francis
Year: 2021
Subjects: subject: Medicine
subject: Physiology
subject: FOS: Biological sciences
subject: FOS: Biological sciences
subject: Pharmacology
subject: 59999 Environmental Sciences not elsewhere classified
subject: FOS: Earth and related environmental sciences
subject: FOS: Earth and related environmental sciences
subject: Ecology
subject: Sociology
subject: FOS: Sociology
subject: FOS: Sociology
subject: Immunology
subject: FOS: Clinical medicine
subject: FOS: Clinical medicine
subject: Cancer

description: As part of the risk management plan in Europe, this study was conducted to characterize drug utilization patterns of Seasonique, a 91 day extended levonorgestrel-containing combined oral contraceptive (COC<sub>LNG</sub>). A retrospective observational study was conducted in France, Italy and Belgium using electronic medical record databases obtained from general practitioners (GPs) in all participating countries and gynecologists in France from 2015 to 2018. The study population included women receiving ≥1 prescription of 91 day COC<sub>LNG</sub> during the study period. Prescribing patterns of 91 day COC<sub>LNG</sub> were examined including: (1) treatment duration; (2) indication; (3) use of combined oral contraceptive (COC) before 91 day COC<sub>LNG</sub> initiation; and (4) switch from and to combined hormonal contraceptives (CHCs) or other contraceptives. Totals of 235, 220, 207 and 659 women using 91 day COC<sub>LNG</sub> were identified in French, Italian and Belgian GP, and French gynecologist databases, respectively. Across databases, 46–76% of women were prescribed a single 91 day COC<sub>LNG</sub> prescription and median treatment duration ranged from 3 to 6 months. The most common indication was contraception (42–81%), followed by menstrual migraines (2–14%). Use of COC during the 6 months prior to 91 day COC<sub>LNG</sub> initiation was 14% across GP databases, but was lower (8%) in the French gynecologist database. The frequency of switching from 91 day COC<sub>LNG</sub> to CHCs or other contraceptives was generally low (5–12%), with the highest proportion being among patients of French gynecologists. Findings indicate that 91 day COC<sub>LNG</sub> was prescribed for relatively short durations and predominantly as indicated for contraception. Most results were comparable across all participating countries. KEY POINTSFindings from this drug utilization study in European databases across general practitioners and French gynecologists confirmed that 91 day extended levonorgestrel-containing combined oral contraceptive (COC<sub>LNG</sub>) was prescribed for relatively short durations (median 3–6 months); predominantly for the intended indication of contraception.Combined oral contraceptive use during the 6 months prior to 91 day COC<sub>LNG</sub> initiation, and switching from 91 day COC<sub>LNG</sub> to combined hormonal contraceptives or other contraceptives, were generally low (14% or less).These findings were mostly consistent across participating countries. Findings from this drug utilization study in European databases across general practitioners and French gynecologists confirmed that 91 day extended levonorgestrel-containing combined oral contraceptive (COC<sub>LNG</sub>) was prescribed for relatively short durations (median 3–6 months); predominantly for the intended indication of contraception. Combined oral contraceptive use during the 6 months prior to 91 day COC<sub>LNG</sub> initiation, and switching from 91 day COC<sub>LNG</sub> to combined hormonal contraceptives or other contraceptives, were generally low (14% or less). These findings were mostly consistent across participating countries.